Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$TGTX Roth Capital Reiterates Buy On TG Therapeutics Following Clinical Study Initiation http://www.smarteranalyst.com/2014/08/15/roth-capital-reiterates-buy-on-tg-therapeutics-following-clinical-study-initiation/
$TGTX Roth Capital Reiterates Buy On TG Therapeutics Following Clinical Study Initiation http://www.smarteranalyst.com/2014/08/15/roth-capital-reiterates-buy-on-tg-therapeutics-following-clinical-study-initiation/
$ACUR Roth Capital Maintains Buy On Acura But Reduces PT To $1.50 Following FDA Meeting Outcome http://www.smarteranalyst.com/2014/08/15/34721/
$ACUR Roth Capital Maintains Buy On Acura But Reduces PT To $1.50 Following FDA Meeting Outcome http://www.smarteranalyst.com/2014/08/15/34721/
$ACUR Roth Capital Maintains Buy On Acura But Reduces PT To $1.50 Following FDA Meeting Outcome http://www.smarteranalyst.com/2014/08/15/34721/
$IAG Roth Capital Reiterates Buy On IAMGOLD, Raises PT To $5.25 http://www.smarteranalyst.com/2014/08/15/roth-capital-reiterates-buy-on-iamgold-raises-pt-to-5-25/
Roth Capital Reiterates Buy On IAMGOLD, Raises PT To $5.25 http://www.smarteranalyst.com/2014/08/15/roth-capital-reiterates-buy-on-iamgold-raises-pt-to-5-25/
Roth Capital Maintains Buy On Summer Infant, Raises PT To $4.50 http://www.smarteranalyst.com/2014/08/15/roth-capital-maintains-buy-on-summer-infant-raises-pt-to-4-50/
$LJPC H.C. Wainwright Reiterates Buy On La Jolla Following 2Q14 Results; Keeps $20 PT http://www.smarteranalyst.com/2014/08/15/h-c-wainwright-reiterates-buy-on-la-jolla-following-2q14-results-keeps-20-pt/
$RXII H.C. Wainwright Reiterates Buy On RXi Pharmaceuticals Following 2Q14 Update http://www.smarteranalyst.com/2014/08/15/h-c-wainwright-reiterates-buy-on-rxi-pharmaceuticals-following-2q14-update/
$RXII H.C. Wainwright Reiterates Buy On RXi Pharmaceuticals Following 2Q14 Update http://www.smarteranalyst.com/2014/08/15/h-c-wainwright-reiterates-buy-on-rxi-pharmaceuticals-following-2q14-update/
$RXII H.C. Wainwright Reiterates Buy On RXi Pharmaceuticals Following 2Q14 Update http://www.smarteranalyst.com/2014/08/15/h-c-wainwright-reiterates-buy-on-rxi-pharmaceuticals-following-2q14-update/
$RXII H.C. Wainwright Reiterates Buy On RXi Pharmaceuticals Following 2Q14 Update http://www.smarteranalyst.com/2014/08/15/h-c-wainwright-reiterates-buy-on-rxi-pharmaceuticals-following-2q14-update/
$AEZS Aeterna Zentaris: Management Is Executing A Productive Turnaround Of The Business, Says Maxim http://www.smarteranalyst.com/2014/08/15/aeterna-zentaris-management-is-executing-a-productive-turnaround-of-the-business-says-maxim/
$DNDN Dendreon: We Would Continue To Recommend Selling Shares, Says Wedbush http://www.smarteranalyst.com/2014/08/15/dendreon-we-would-continue-to-recommend-selling-shares-says-wedbush/
$DNDN Dendreon: We Would Continue To Recommend Selling Shares, Says Wedbush http://www.smarteranalyst.com/2014/08/15/dendreon-we-would-continue-to-recommend-selling-shares-says-wedbush/
$DNDN Dendreon: We Would Continue To Recommend Selling Shares, Says Wedbush http://www.smarteranalyst.com/2014/08/15/dendreon-we-would-continue-to-recommend-selling-shares-says-wedbush/
Dendreon: We Would Continue To Recommend Selling Shares, Says Wedbush http://www.smarteranalyst.com/2014/08/15/dendreon-we-would-continue-to-recommend-selling-shares-says-wedbush/
Autodesk: Investors Are Likely To See Reasonably Good 12-month Upside, Says Wedbush http://www.smarteranalyst.com/2014/08/15/autodesk-investors-are-likely-to-see-reasonably-good-12-month-upside-says-wedbush/
$OVTI Wedbush Maintains Neutral On Omnivision Following Hua Capital Non-Binding Proposal http://www.smarteranalyst.com/2014/08/15/wedbush-maintains-neutral-on-omnivision-following-hua-capital-non-binding-proposal/
$OVTI Wedbush Maintains Neutral On Omnivision Following Hua Capital Non-Binding Proposal http://www.smarteranalyst.com/2014/08/15/wedbush-maintains-neutral-on-omnivision-following-hua-capital-non-binding-proposal/
$OVTI Wedbush Maintains Neutral On Omnivision Following Hua Capital Non-Binding Proposal http://www.smarteranalyst.com/2014/08/15/wedbush-maintains-neutral-on-omnivision-following-hua-capital-non-binding-proposal/
Wedbush Maintains Neutral On Omnivision Following Hua Capital Non-Binding Proposal http://www.smarteranalyst.com/2014/08/15/wedbush-maintains-neutral-on-omnivision-following-hua-capital-non-binding-proposal/
Wedbush Maintains Neutral On Lowe’s Companies Ahaed Of 2Q14 Results http://www.smarteranalyst.com/2014/08/15/wedbush-maintains-neutral-on-lowes-companies-ahaed-of-2q14-results/
$INTC Wedbush Reiterates Neutral On Intel Following Acquisition Of LSI’s Axxia Networking Business http://www.smarteranalyst.com/2014/08/15/wedbush-reiterates-neutral-on-intel-following-acquisition-of-lsis-axxia-networking-business/
$INTC Wedbush Reiterates Neutral On Intel Following Acquisition Of LSI’s Axxia Networking Business http://www.smarteranalyst.com/2014/08/15/wedbush-reiterates-neutral-on-intel-following-acquisition-of-lsis-axxia-networking-business/
Wedbush Reiterates Neutral On Intel Following Acquisition Of LSI’s Axxia Networking Business http://www.smarteranalyst.com/2014/08/15/wedbush-reiterates-neutral-on-intel-following-acquisition-of-lsis-axxia-networking-business/
$AAP Advance Auto Parts: Story Integration And Core Business Turnaround Story Remains On Track, Says Wedbush http://www.smarteranalyst.com/2014/08/15/advance-auto-parts-story-integration-and-core-business-turnaround-story-remains-on-track-says-wedbush/
$AAP Advance Auto Parts: Story Integration And Core Business Turnaround Story Remains On Track, Says Wedbush http://www.smarteranalyst.com/2014/08/15/advance-auto-parts-story-integration-and-core-business-turnaround-story-remains-on-track-says-wedbush/
Advance Auto Parts: Story Integration And Core Business Turnaround Story Remains On Track, Says Wedbush http://www.smarteranalyst.com/2014/08/15/advance-auto-parts-story-integration-and-core-business-turnaround-story-remains-on-track-says-wedbush/
Evercore Analysts Set Expectations On Cisco Systems Into Earnings http://www.smarteranalyst.com/2014/08/14/evercore-analysts-set-expectations-on-cisco-systems-into-earnings/
$CNAT Conatus Pharmaceuticals: NASH Trial Results Delay Is A Non-Issue, Says Roth Capital http://www.smarteranalyst.com/2014/08/14/conatus-pharmaceuticals-nash-trial-results-delay-is-a-non-issue-says-roth-capital/
$ADHD Roth Capital Reiterates Buy On Alcobra On The Heels Of Fragile X Opportunity http://www.smarteranalyst.com/2014/08/14/roth-capital-reiterates-buy-on-alcobra-on-the-heels-of-fragile-x-opportunity/
$CPRX Catalyst Bullish Stance Reiterated At Roth Capital Following 2Q14 Results http://www.smarteranalyst.com/2014/08/14/catalyst-pharmaceutical-bullish-stance-reiterated-at-roth-capital-following-2q14-results/
$TKMR Maxim Maintains Buy On Tekmira Pharmaceuticals Following 2Q14 Results
http://www.smarteranalyst.com/2014/08/14/maxim-maintains-buy-on-tekmira-pharmaceuticals-following-2q14-results/
$TKMR Maxim Maintains Buy On Tekmira Pharmaceuticals Following 2Q14 Results
http://www.smarteranalyst.com/2014/08/14/maxim-maintains-buy-on-tekmira-pharmaceuticals-following-2q14-results/
$SYN Maxim Maintains Buy On Synthetic Biologics Following 2Q14 Results http://www.smarteranalyst.com/2014/08/14/maxim-maintains-buy-on-synthetic-biologics-following-2q14-results/
$SYN Maxim Maintains Buy On Synthetic Biologics Following 2Q14 Results http://www.smarteranalyst.com/2014/08/14/maxim-maintains-buy-on-synthetic-biologics-following-2q14-results/
Maxim Maintains Buy On Synthetic Biologics Following 2Q14 Results http://www.smarteranalyst.com/2014/08/14/maxim-maintains-buy-on-synthetic-biologics-following-2q14-results/
$TKMR Maxim Maintains Buy On Tekmira Pharmaceuticals Following 2Q14 Results
http://www.smarteranalyst.com/2014/08/14/maxim-maintains-buy-on-tekmira-pharmaceuticals-following-2q14-results/